On October 14, 2025 Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, reported that it has received the first milestone payment under its licensing and collaboration agreements with Shell BioTech and a third party.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In 2020 Forlong and Shell BioTech, a CDMO in China, entered a technology development collaboration to leverage Forlong’s proprietary Fbody Technology Platform to develop long half-life peptide therapy for a third party. In 2025, Forlong and Shell BioTech entered into a licensing agreement with the third party for selected protein therapy candidates incorporating Fbody, and amended the initial collaboration agreement to restructure terms including upfront and milestones payments as well as royalty on future product sales. Following the upfront payment in 2025, this is the first milestone payment, triggered by IND submission for the Fbody-fusion protein therapy by the third party to China National Medical Products Administration.
Fbody Long-acting Technology is one of synthetic immunology platforms of Forlong. It is a single-chain Fc engineered to maintain FcRn affinity while eliminating binding of FcγRs and complement systems, aiming to optimize protein half-life and biodistribution. Forlong’s lead clinical candidate FL115 is an interleukin-15 (IL-15) superagonist incorporating Fbody. It is in multiple clinical studies in China and the United States, showing favorable safety profile and preliminary clinical responses in patients with advanced solid tumors, and is currently being advanced to combo therapy with PD-(L)1 antibodies in Phase I for patients with advanced solid tumors and combo therapy with Bacillus Calmette-Guérin (BCG) in Phase II for patients with nonmuscle invasive bladder cancer (NMIBC).
"We are excited to see another Fbody fusion protein therapy advancing into clinic, a significant milestone for our synthetic immunology platforms," said Dong Wei, Ph.D., Chief Executive Officer of Forlong Biotechnology, "FL115’s best-in-class potential in the challenging IL-15 superagonist class first showcased unique properties of Fbody, and this milestone further validates its ability to enhance profiles for variety of proteins beyond cytokines, and success of our out-licensing strategy and its ability to drive real-world impact through partnerships."
(Press release, Forlong Biotechnology, OCT 14, 2025, View Source [SID1234656666])